RU2019104870A - Комбинированный тест на наличие колоректального рака - Google Patents

Комбинированный тест на наличие колоректального рака Download PDF

Info

Publication number
RU2019104870A
RU2019104870A RU2019104870A RU2019104870A RU2019104870A RU 2019104870 A RU2019104870 A RU 2019104870A RU 2019104870 A RU2019104870 A RU 2019104870A RU 2019104870 A RU2019104870 A RU 2019104870A RU 2019104870 A RU2019104870 A RU 2019104870A
Authority
RU
Russia
Prior art keywords
patient
cell
colorectal cancer
free nucleosome
detecting
Prior art date
Application number
RU2019104870A
Other languages
English (en)
Russian (ru)
Other versions
RU2019104870A3 (https=
Inventor
Якоб Винсент МИКАЛЛЕФ
Ясон ТЕРРЕЛ
Original Assignee
Белджиан Волишн Спрл
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Белджиан Волишн Спрл filed Critical Белджиан Волишн Спрл
Publication of RU2019104870A publication Critical patent/RU2019104870A/ru
Publication of RU2019104870A3 publication Critical patent/RU2019104870A3/ru

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57535Immunoassay; Biospecific binding assay; Materials therefor for cancer of the large intestine, e.g. colon, rectum or anus
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6875Nucleoproteins
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/72Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood pigments, e.g. haemoglobin, bilirubin or other porphyrins; involving occult blood
    • G01N33/721Haemoglobin
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/154Methylation markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/70Mechanisms involved in disease identification

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
RU2019104870A 2016-07-25 2017-07-25 Комбинированный тест на наличие колоректального рака RU2019104870A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1612815.9A GB201612815D0 (en) 2016-07-25 2016-07-25 Novel combination test
GB1612815.9 2016-07-25
PCT/EP2017/068754 WO2018019827A1 (en) 2016-07-25 2017-07-25 Combination test for colorectal cancer

Publications (2)

Publication Number Publication Date
RU2019104870A true RU2019104870A (ru) 2020-08-25
RU2019104870A3 RU2019104870A3 (https=) 2020-12-01

Family

ID=56894403

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2019104870A RU2019104870A (ru) 2016-07-25 2017-07-25 Комбинированный тест на наличие колоректального рака

Country Status (16)

Country Link
US (1) US20200182875A1 (https=)
EP (1) EP3488238B1 (https=)
JP (1) JP6983221B2 (https=)
KR (1) KR102442803B1 (https=)
CN (1) CN109791154A (https=)
AU (1) AU2017301970B2 (https=)
BR (1) BR112019001384A2 (https=)
CA (1) CA3031580A1 (https=)
GB (1) GB201612815D0 (https=)
IL (1) IL264359B2 (https=)
MY (1) MY193895A (https=)
RU (1) RU2019104870A (https=)
SG (2) SG10202100630SA (https=)
TW (1) TWI776816B (https=)
WO (1) WO2018019827A1 (https=)
ZA (1) ZA201808601B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201906199D0 (en) * 2019-05-02 2019-06-19 Belgian Volition Sprl Method for the detection of cancer
WO2021024009A1 (en) * 2019-08-02 2021-02-11 Shanghai Yunxiang Medical Technology Co., Ltd. Methods and compositions for providing colon cancer assessment using protein biomarkers
CN112345766B (zh) * 2020-10-22 2024-02-02 中国工程物理研究院核物理与化学研究所 一种荧光-放射性联用的体外靶向筛选方法
TW202242146A (zh) * 2021-01-13 2022-11-01 比利時商比利時意志有限公司 肺癌的檢測方法
EP4291899A1 (en) * 2021-02-11 2023-12-20 EDP Biotech Corporation Kits and methods for detecting markers and determining the presence or risk of cancer
WO2024223947A1 (en) * 2023-04-28 2024-10-31 Belgian Volition Srl Use of cell free nucleosomes as biomarkers of carcinomas
CN116973572B (zh) * 2023-06-02 2025-03-07 东南大学附属中大医院 基于血、粪便铁蛋白检测评估肠屏障损伤严重程度的方法
CN116718775B (zh) * 2023-08-04 2023-10-27 天津迈基生物科技有限公司 一种检测结直肠癌的组合物、试纸及方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2541178T3 (es) * 2009-02-03 2015-07-16 Mdxhealth Sa Método de detección de cáncer colorrectal
WO2010120942A2 (en) * 2009-04-14 2010-10-21 The Regents Of The University Of California Histone modification patterns for clinical diagnosis and prognosis of cancer
US8568984B2 (en) * 2010-02-19 2013-10-29 Philadelphia Health & Education Corporation Methods of diagnosing non-urinary tract diseases by detecting aberrant methylation
JP2012018119A (ja) * 2010-07-09 2012-01-26 Toray Ind Inc 大腸癌検出用マーカーおよびそれを用いた大腸癌検出方法
CN103328500B (zh) * 2010-08-04 2018-01-26 西兹尔生物技术有限公司 用于癌症的诊断和治疗的方法和化合物
GB201115098D0 (en) * 2011-09-01 2011-10-19 Belgian Volition Sa Method for detecting nucleosomes containing histone variants
PT2788767T (pt) * 2011-12-07 2017-12-06 Belgian Volition Sprl Método de detecção de adutos de nucleosoma
EP4001436B1 (en) * 2012-05-11 2024-03-13 Clinical Genomics Pty. Ltd. Diagnostic gene marker panel

Also Published As

Publication number Publication date
MY193895A (en) 2022-10-31
IL264359B2 (en) 2024-03-01
EP3488238B1 (en) 2023-06-07
TW201804156A (zh) 2018-02-01
TWI776816B (zh) 2022-09-11
IL264359B1 (en) 2023-11-01
AU2017301970A1 (en) 2019-01-17
KR102442803B1 (ko) 2022-09-15
JP6983221B2 (ja) 2021-12-17
CN109791154A (zh) 2019-05-21
BR112019001384A2 (pt) 2019-04-30
US20200182875A1 (en) 2020-06-11
IL264359A (en) 2019-02-28
EP3488238A1 (en) 2019-05-29
ZA201808601B (en) 2019-09-25
WO2018019827A1 (en) 2018-02-01
GB201612815D0 (en) 2016-09-07
EP3488238C0 (en) 2023-06-07
JP2019527361A (ja) 2019-09-26
SG11201900329XA (en) 2019-02-27
KR20190039089A (ko) 2019-04-10
AU2017301970B2 (en) 2023-04-27
RU2019104870A3 (https=) 2020-12-01
SG10202100630SA (en) 2021-03-30
CA3031580A1 (en) 2018-02-01

Similar Documents

Publication Publication Date Title
RU2019104870A (ru) Комбинированный тест на наличие колоректального рака
Bahadır et al. Applications of electrochemical immunosensors for early clinical diagnostics
Kaczor‐Urbanowicz et al. Emerging technologies for salivaomics in cancer detection
Bakirhan et al. Recent progress on the sensitive detection of cardiovascular disease markers by electrochemical-based biosensors
Farzin et al. Recent advances in design of electrochemical affinity biosensors for low level detection of cancer protein biomarkers using nanomaterial-assisted signal enhancement strategies
Shah et al. Biomarkers for early detection of colorectal cancer and polyps: systematic review
Zhao et al. Levels of plasma Epstein-Barr virus DNA prior and subsequent to treatment predicts the prognosis of nasopharyngeal carcinoma
JP2008542703A5 (https=)
JP2018504609A5 (https=)
US20180080937A1 (en) Biomarker Panel For Diagnosing Cancer
RU2014112350A (ru) Способ детекции нуклеосом, содержащих нуклеотиды
JP2019527361A5 (https=)
Roe et al. Mesothelin-related predictive and prognostic factors in malignant mesothelioma: a nested case–control study
JP2016500110A5 (https=)
Pardi et al. Predicting relapse in patients with inflammatory bowel disease: what is the role of biomarkers?
Beretov et al. Proteomics for breast cancer urine biomarkers
Kammer et al. Noninvasive biomarkers for lung cancer diagnosis, where do we stand?
JP2009538607A5 (https=)
Bilegsaikhan et al. Circulating miR‐338‐5p is a potential diagnostic biomarker in colorectal cancer
Werner et al. Evaluation of the diagnostic value of 64 simultaneously measured autoantibodies for early detection of gastric cancer
WO2015100459A3 (en) Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies
JP2018529931A5 (https=)
JP2020514689A5 (https=)
CY1119797T1 (el) Λακτοφερινη για χρηση στη διαγνωση και προγνωση της νοσου alzheimer
Dekker et al. Lack of standards for the detection of melanoma in sentinel lymph nodes: a survey and recommendations